Can-Fite BioPharma (CANF) Q4 2025 earnings summary

Executive summary

• Achieved positive clinical milestones, including Phase 2a safety endpoint in pancreatic cancer and a 9-year cancer-free survival in a liver cancer patient treated with Namodenoson.

• Expanded Namodenoson's indications into metabolic diseases and obesity, supported by new scientific findings and patent allowances.

• Strengthened intellectual property portfolio with new patents in Israel, Canada, and Brazil, enhancing long-term commercial positioning.

Financial highlights

• Revenues for 2025 were $0.41 million, down 40% year-over-year due to lower recognition of advance payments from distribution agreements.

• Research and development expenses rose 16.3% to $6.69 million, driven by accelerated clinical trial activity for Namodenoson and Piclidenoson.

• General and administrative expenses increased 20.2% to $3.66 million, mainly from higher investor relations costs.

• Net loss widened to $9.83 million from $7.88 million in 2024, primarily due to higher R&D and administrative expenses.

• Cash and cash equivalents plus short-term deposits totaled $8.54 million at year-end 2025, up from $7.88 million in 2024.

Outlook and guidance

• General and administrative expenses are expected to remain stable through 2026.

• Ongoing clinical trials and expanded indications position the company for potential value creation in the near and long term.